Oric Pharmaceuticals, Inc. ORIC 深 沪
等待开盘 06-26 09:30:00 美东时间
9.455
+0.025
+0.27%
华盛通- 最 高9.99
- 今 开9.53
- 成交量 136.39万股
- 最 低 8.67
- 昨 收 9.43
- 总市值 37.33万
- 52周最高 14.93
- 市盈率 静 --
- 换手率 3454.70%
- 52周最低 7.23
- 委 比 38.79%
- 总股本 3.95万
- 历史最高 40.81
- 量 比 0.93
- 振 幅 14.00%
- 历史最低 1.10
- 每 手 1
- 风险率 1.63%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Market-Moving News for April 1st
NKE: -10% | Nike shares are trading lower after the company reported Q3 financial results. Also, the company issued Q4 sales guidance below estimates. ORIC: -36% | Oric Pharmaceuticals shares are trading
04-01 19:16
ORIC Pharmaceuticals Completes Dose Exploration Part Of ORIC-944 Phase 1b Trial
ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today reported financial results and provided clinical and
2025-11-14 05:25
长宏国际交付第二艘11500TEU双燃料集装箱船
7月16日，长宏国际为地中海航运（MSC）建造的第二艘11500箱LNG双燃料集装箱船“MSC INSA”号（CHB2028）命名交付。 地中海航运现场经理J...
2025-07-17 13:06
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
ORIC Pharmaceuticals授予5月入职的3位新员工合计39,100份非合格股票期权和6,500股限制性股票单位，作为雇佣激励，按2022股权激励计划执行。
2025-06-06 20:30
ORIC® Pharmaceuticals Announces $125 Million Private Placement Financing
ORIC Pharmaceuticals has secured approximately $125 million in a private placement led by SR One, with participation from several institutional investors. The funds will be used for research and development of their clinical-stage products, including the ORIC-944 Phase 3 trial for prostate cancer, and are expected to sustain operations through mid-2027.
2025-05-28 20:05
里程碑突破！全球首个实体瘤CAR-T有望到来
（转自：药剂Talks） 长久以来，CAR-T疗法在血液瘤领域光芒四射，而在实体瘤的广袤宇宙中却徘徊不前。但如今，这一局面正悄然生变。 今年2月，国际顶级期刊...
2025-05-28 08:52
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
ORIC Pharmaceuticals announced it will participate in two investor conferences in June: the Jefferies Global Healthcare Conference on June 4 and the Goldman Sachs Global Healthcare Conference on June 10. Details and webcasts will be available on its website.
2025-05-27 20:30
ORIC® Pharmaceuticals to Present Initial Data from Phase 1b Trial of ORIC-944 in Combination with Androgen Receptor Inhibitors in Patients with mCRPC
ORIC Pharmaceuticals to present Phase 1b data on ORIC-944 for metastatic prostate cancer in conference call on May 28, 2025. ORIC-944 is a PRC2 inhibitor targeting treatment-resistant prostate cancer.
2025-05-27 12:00
Cantor Fitzgerald Reiterates Overweight on ORIC Pharmaceuticals
Cantor Fitzgerald analyst Prakhar Agrawal reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Overweight.
2024-09-10 01:19
Stifel Initiates Coverage On ORIC Pharmaceuticals with Buy Rating, Announces Price Target of $20
Stifel analyst Bradley Canino initiates coverage on ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy rating and announces Price Target of $20.
2024-09-06 23:28
